CAR T-Cell Therapy for Relapsed or Refractory B-ALL
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new CAR T-cell therapy (called RD06-03) for people whose B-cell acute lymphoblastic leukemia (B-ALL) has returned or hasn't responded to other treatments. It aims to see if the therapy is safe and can help fight the leukemia.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 3 and 70 years old.
- You have B-cell acute lymphoblastic leukemia (B-ALL) that has come back or hasn't responded to standard treatments.
- Your leukemia cells have the CD19 protein on them (your doctor can check this).
- Your organs (like liver, kidneys, and heart) are working well enough based on standard tests.
- You are not pregnant or breastfeeding, and agree to use effective birth control during and for 6 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immunotherapy called CAR-T cells, which are made from your own blood cells and trained to find and destroy leukemia cells. It is for adults with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to standard treatments.
This trial tests a new type of CAR-T cell therapy that is engineered to be more effective against a specific kind of leukemia (B-ALL) that has returned or not responded to treatment. The therapy uses a patient's own immune cells to target and destroy cancer cells.
This trial tests a personalized cell therapy (CAR-T) for people with B-cell acute lymphoblastic leukemia (ALL) that has come back after treatment or is hard to treat. The therapy uses your own immune cells, modified to find and kill leukemia cells.
This trial tests whether specially designed immune cells (CAR T cells) that target CD19 can help adults whose B-cell acute lymphoblastic leukemia has not responded to standard treatments or has returned. The cells are made from your own blood and given back to you after a short chemotherapy preparation.
This trial tests a new type of CAR T cell therapy that targets two proteins (CD19 and CD22) found on leukemia cells. It is for children and young adults whose B-ALL has come back multiple times, or who have not responded to other treatments.
This trial is testing a new CAR-T cell therapy (Senl_B19) for children and young adults with B-cell acute lymphoblastic leukemia (B-ALL) that has returned or not responded to treatment. It targets a protein called CD19 on leukemia cells to help your immune system attack the cancer.
Hear when a new B Lymphoblastic Leukemia/Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.